Zhou et al. demonstrated the EZH2 inhibition-mediated beneficial effects on leukemia cells and prolonged survival of CML mice were compromised by the concurrent transduction of shRNA targeting PTEN [68]. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.